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Alternaria-derived serine protease activity drives
IL-33–mediated asthma exacerbations
Robert J. Snelgrove, PhD,* Lisa G. Gregory, PhD,* Teresa Peiro, PhD, Samia Akthar, MSc, Gaynor A. Campbell, PhD,
Simone A. Walker, MSc, and Clare M. Lloyd, PhD London, United KingdomAbbreviations used
AEBSF: 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride
ALT: Alternaria
BALF: BAL fluid
CAT: Cat dander
HDM: House dust mite
MCPT-1: Mast cell protease-1
MMP-9: Matrix metalloproteinase-9
PAP: Papain
PAR-2: Protease activated receptor 2
RAG: Ragweed
TRYP: TrypsinBackground: The fungal allergen Alternaria alternata is
implicated in severe asthma and rapid onset life-threatening
exacerbations of disease. However, the mechanisms that
underlie this severe pathogenicity remain unclear.
Objective: We sought to investigate the mechanism whereby
Alternaria was capable of initiating severe, rapid onset allergic
inflammation.
Methods: IL-33 levelswerequantified inwild-typeandST22/2mice
that lacked the IL-33 receptor given inhaled house dust mite, cat
dander, or Alternaria, and the effect of inhibiting allergen-specific
protease activities on IL-33 levels was assessed. An exacerbation
model of allergic airway disease was establishedwherebymice were
sensitizedwithhousedustmitebefore subsequentlybeingchallenged
with Alternaria (with or without serine protease activity), and
inflammation, remodeling, and lung functionassessed24hours later.
Results: Alternaria,butnot othercommonaeroallergens, possessed
intrinsic serine protease activity that elicited the rapid release of
IL-33 into the airways of mice through a mechanism that was
dependent upon the activation of protease activated receptor-2 and
adenosine triphosphate signaling.TheuniquecapacityofAlternaria
to drive this early IL-33 release resulted in a greater pulmonary
inflammation by 24 hours after challenge relative to the common
aeroallergen house dust mite. Furthermore, this Alternaria serine
protease–IL-33 axis triggered a rapid, augmented inflammation,
mucus release, and loss of lung function in our exacerbationmodel.
Conclusion: Alternaria-specific serine protease activity causes
rapid IL-33 release, which underlies the development of a
robust TH2 inflammation and exacerbation of allergic airway
disease. (J Allergy Clin Immunol 2014;134:583-92.)
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http://dx.doi.org/10.1016/j.jaci.2014.02.002Asthma is characterized by reversible airway obstruction as a
result of a predominantly TH2-driven airway inflammation and
pulmonary remodeling. For individuals who exhibit a genetic
predisposition, asthma can be induced or exacerbated by an
abnormal response to environmental stimuli, such as allergens,
infectious agents, or airborne pollutants. In addition to activation
of pattern recognition receptors, many allergens possess intrinsic
proteolytic activities that play an important role in development
of allergic airway disease, in part, by activation of protease-
activated receptors (PAR). IL-33 has been associated with the
development and maintenance of allergic asthma via ligation of
its receptor ST2.1 IL-33 is located within the nucleus of Type II
epithelial cells in the lung, but mechanisms that dictate its release
remain ambiguous. It has been suggested that IL-33 can be released
during necrosis in response to infection or trauma, and subse-
quently functions as an ‘‘alarmin.’’2,3 Pulmonary IL-33 expression
is elevated with individuals with asthma, which correlates with
asthma severity.4,5 Modulation of the IL-33–ST2 axis in murine
models of allergic airway disease has supported a prominent role
for this cytokine in asthma.6-12 Genetic analysis also has linked
polymorphisms in human IL-33–ST2 to the incidence of asthma.13
Severe asthma with fungal sensitization is characterized by the
presence of severe asthma, fungal sensitization, and the exclusion
of bronchopulmonary aspergillosis.14 Epidemiologic studies have
identified sensitivity to fungal allergens as a prominent cause of
allergic asthma.15 An association exists between sensitivity to
the widely distributed fungus Alternaria alternata and asthma
severity, hospital admission, and fatal asthma exacerba-
tions.14,16-23 High Alternaria spore counts are detected in late
summer and/or early autumn, where dispersion of spores is
associated with thunderstorms and leads to increased morbidity
and mortality.18,19,24-26 The prevalence of severe asthma with
fungal sensitization has been estimated to be as frequent as
30%, although why molds are implicated in severe asthma
compared with other aeroallergens has not been elucidated.583
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activities that have the potential to act as adjuvants in driving a pro-
longed TH2 inflammation.
27,28 Although the exact mechanism that
defines this potential remains poorly defined, TLR4 activation has
been implicated.29 Alternaria-specific serine protease activity
has previously been demonstrated to elicit epithelial cell increases
in intracellular calcium through protease activated receptor 2
(PAR-2) activation and to drive pulmonary inflammation.30 In the
present study, we demonstrate that Alternaria-specific serine
protease activity promotes the release of IL-33 in a murine model,
which subsequently drives a robust release of early innate
mediators and TH2 pulmonary inflammation. Importantly, this
serine protease–mediated IL-33 release was shown to underlie
Alternaria-driven severe exacerbations of allergic airway disease.METHODS
Mice
Female BALB/c mice (Charles River, Margate, United Kingdom) and
ST22/2 mice on a BALB/c background (a kind gift from Andrew McKenzie,
MRC Laboratory of Molecular Biology, Cambridge, United Kingdom), 6 to 8
weeks old received10mghouse dustmite (HDM) (Dermatophagoides pteronys-
sinus), Alternaria alternata, cat dander, or ragweed (Ambrosia artemisiifolia)
extract (Greer, Lenoir, NC); papain or trypsin (Sigma-Aldrich, Dorset, United
Kingdom); or 50 mL of vehicle, PBS intranasally. Mice were culled either 1 or
24 hours after challenge. In some experiments, the Alternaria extract was prein-
cubated with either 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride
(AEBSF) (25 mg/mL) or suramin (2 mM) (Sigma-Aldrich). FSSLYR-amide
(Bachem AG, Bubendorf, Switzerland) was administered 30 minutes before
allergen challenge (100 mg intraperitoneal and 12.5 mg intranasal). In the exac-
erbation protocol, mice were treated with either 15 mg HDM or PBS 3 times a
week for 3 weeks before receiving single challenge with 10 mg Alternaria. All
the experiments were performed in accordance with UK Home Office guide-
lines. Airway responsiveness was determined by direct measurements of lung
function inanesthetizedand tracheostomizedmice24hours after final challenge.
Tissue processing
Serum,BALfluid (BALF)and lung tissuewere collected.31Paraffin-embedded
sections (4 mm) were stained with hematoxylin and eosin and periodic
acid–Schiff. Paraffin sections were stained with goat anti-mouse IL-33 (R&D
Systems, Abingdon, United Kingdom) by using an avidin-biotin stainingmethod.
Mediator analysis
BALF was analyzed by ELISA: IL-4, IL-5 (PharMingen, Oxford, United
Kingdom), IL-13, IL-33, IL-25, matrix metalloproteinase-9 (MMP-9) (R&D
Systems), IL-1b (eBioscience, Hatfield, United Kingdom), and albumin (Bethyl
Laboratories, Montgomery, Tex). Uric acid was measured using an Amplex red
uric acid/uricase assay kit (Invitrogen, Paisley, United Kingdom). Lactate
dehydrogenase was measured by using an In Vitro Toxicology Assay kit
(Sigma-Aldrich). Serum mast cell protease (MCP-1) was measured by ELISA
(eBioscience, Hatfield, United Kingdom). IL-33 size was determined byWestern
blot.MMP-9activitywasdeterminedbyusingNovex10%zymogramgelatingels
(Invitrogen). MUC5AC transcript levels were determined by quantitative PCR.
Flow cytometric analysis
Disaggregated lung cells were restimulated with 500 ng/mL of ionomycin and
50 ng/mL of phorbol 12-myristate 13-acetate in the presence of brefeldin A (BD
Pharmingen, Oxford, United Kingdom). Cells were stained for CD3, CD4, CD8,
IL-13, IL-17, or IFN-g (eBioscience). In addition, cells were stained with Ly-6G,
SiglecF, CD11b, CD11c, F4/80, CD45, lineage negative cocktail (eBioscience),
T1/ST2 (Morwell Diagnostics, Zurich, Switzerland), or ICOS (Biolegend,
London, United Kingdom). Labeled cells were acquired on a BD Fortessa (BD
Bioscience, Oxford, United Kingdom), and analyzed by using FlowJo (Treestar,
Ashland, Ore).Statistical analysis
Data were analyzed by using Prism 4 (GraphPad Software Inc, La Jolla,
Calif). Multiple comparisons were performed by using the Kruskal-Wallis
test. A 2-tailed P value was determined by the Mann-Whitney test
when comparing between 2 groups. Additional detail on the methods used
in the present study are provided in this article’s Online Repository at www.
jacionline.org.RESULTS
Alternaria-specific serine protease activity drives an
early IL-33–mediated inflammation
Mice were treated intranasally with a panel of allergen extracts
and the response to challenge determined after 1 hour. Papain and
trypsin also were tested as examples of cysteine and serine
proteases, respectively. Strikingly, Alternaria treatment resulted
in a robust early IL-33 release, which was not observed in
heat-treated Alternaria or with any other allergens and/or
proteases (Fig 1, A). The failure to detect IL-33 in response to
these other allergens was not a consequence of them eliciting
IL-33 release and subsequently cleaving the cytokine into
immunologically undetectable fragments (data not shown).
From Western blots of the BALF, we determined that released
IL-33was a full-length protein (Fig 1,B). Therewas no significant
increase in inflammatory cells to the lung or BALF (see Fig E1, A
in this article’s Online Repository at www.jacionline.org), which
suggests that IL-33 release was from lung resident cells. The
source of IL-33 in the BALF of Alternaria-exposed mice
appeared to be Type II epithelial cells because they stained
strongly for IL-33 in control mice, whereas the number of
these IL-331 cells was significantly reduced 1 hour after
Alternaria exposure (Fig 1, C). The release of preformed IL-33
into the airways in response to Alternaria was confirmed by the
concomitant reduction of IL-33 levels in lung tissue (Fig E1, B).
Cellular damage results in lactate dehydrogenase release, and
levels were modestly elevated in BALF in response to Alternaria,
but, greater still after papain exposure, an enzyme that failed to
elicit IL-33 release (Fig E1, C). Similarly, although the alarmin
uric acid also was released in response to Alternaria, papain
again induced greater release (Fig E1, D). Thus, taken
together, theAlternaria-induced increase in IL-33 release appears
to be independent of cellular damage. BALF albumin levels
were significantly elevated by Alternaria but also by papain
(Fig E1, E), which suggests that loss of epithelial barrier function
alone and influx of extrapulmonarymediators also is not sufficient
to account for theAlternaria-induced IL-33. Aswith IL-33, IL-1b
was only detectable in Alternaria-exposed animals (Fig 1, D).
Similarly, MMP-9 secretion was observed in Alternaria and to
a lesser extent papain and cat dander–treated mice (Fig 1, E).
Furthermore, serum mast cell protease (MCPT-1) levels also
were significantly increased in response to Alternaria (Fig 1, F).
Alternaria-induced IL-33 release in vitro has previously been
reported to be ATP signalling dependent.32 Accordingly,
blockade of ATP signaling in vivo through administration of P2
receptor antagonist suramin resulted in a 50% reduction in
IL-33 release in response to Alternaria at 1 hour (Fig 2, A).
Similarly, blocking PAR-2 receptor activation by endogenous
proteases in the allergen inhibited IL-33 release into the BALF
in response to Alternaria by 68% (Fig 2, A). The failure to
completely abrogate IL-33 release by these inhibitors and/or
antagonists may reflect redundancy within pathways. Because
FIG 1. Acuteallergen-inducedmediator release.A, IL-33 levels in theBALFofmice treatedwithHDM,Alternaria
(ALT), cat dander (CAT), ragweed (RAG), papain (PAP), or trypsin (TRYP). ‘‘B’’ denotesboiledextract.B,Western
blot of IL-33 protein in BALF. C, Immunohistochemistry, demonstrating alveolar epithelial expression of IL-33
(brownstainedcells). IL-1b (D)andMMP-9 levels in theBALF (E).F,SerumMCPT-1 levels.Dataarepresentedas
mean 6 SEM (3 mice per treatment group). *P < .05 compared with PBS-treated mice. Representative
photomicrographs are shown. Original magnification340. Scale bar5 50 mm.
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may be mediated by an Alternaria-specific protease activity. The
proteSEEKER (G-Biosciences, St Louis, Mo) assay was used to
determine the relative protease activities present in different
allergens. Cysteine protease activity was unique to HDM,
whereas serine proteases also were present in Alternaria, cat
dander, and ragweed (see Table E1 in this article’s Online
Repository at www.jacionline.org).
The role of endogenous serine proteases in driving IL-33
release was determined by preincubating Alternaria with the
serine protease inhibitor AEBSF before administration to mice.
Intriguingly, the Alternaria-induced increase in IL-33 at 1 hour
was almost completely dependent on serine protease activity
(Fig 2, B). Because Alternaria exhibits slightly greater total and
serine protease activity relative to HDM (see Fig E2, A and B in
this article’s Online Repository at www.jacionline.org), it is
conceivable that the Alternaria specific IL-33 release is a function
of greater protease activity of this allergen. To verify that this was
not the case, it was demonstrated that even 10 times the dose ofHDM failed to instigate IL-33 release (Fig E2, C). Furthermore,
the Alternaria-induced increase in IL-1b, MCPT-1, and MMP-9
were ablated by AEBSF (Fig 2, C-E). The increase in MMP-9
releasewas confirmed byWestern blot (Fig 2, F) and zymography
(Fig 2, G). We subsequently determined whether IL-33 signaling
through ST2 was critical for this innate mediator secretion by
assessing their levels in Alternaria-exposed ST2KO mice.
MCPT-1 (Fig 2, D) and MMP-9 release (Fig 2, E-G) were
critically dependent on ST2 signaling and thus secondary to
IL-33 release. In contrast, Alternaria induced IL-1b production
was independent of ST2 signaling (Fig 2, C).
Alternaria-derived serine protease activity drives
early pulmonary cellular infiltrate
To elucidate the role of Alternaria serine proteases and ensuing
IL-33 release in driving early pulmonary inflammation, we
assessed cellular recruitment at 24 hours in wild-type mice exposed
to Alternaria with or without pretreatment with AEBSF, and
Alternaria-exposed ST2KO mice. Alternaria exposure increased
FIG 2. Serine proteasesmediate innatemediator release. BALF IL-33 (A and B), IL-1b (C), and serumMCPT-1
(D) levels of mice treated with either HDM or Alternaria (Alt). E,MMP-9 levels in the BALF. F,Western blot of
MMP-9 and gelatin zymogram (G) for MMP-9 activity. Data are presented as mean 6 SEM (8-10 mice per
treatment group). Representative photomicrographs of gel images are shown. *P < .05 compared with
PBS-treated mice. P < .05 compared with Alternaria-treated mice.
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(Fig 3, A) at 24 hours. This infiltrate was predominantly neutrophilic
(Fig 3, B), with an elevation of eosinophils and macrophages also
apparent (Fig 3, C and D). Inhibition of endogenous allergen serine
proteases or the absence of ST2 receptor significantly
reduced neutrophilia, eosinophilia, and recruitment of tissue
macrophages (Fig 3, A-D). In contrast, neutrophils were the only
cell type elevated after HDM administration (Fig 3, B-D). IL-13
and IL-5 were elevated 24 hours after Alternaria administration
(Fig 3, E and F), and independent of IL-33 signaling via the ST2
receptor. Interestingly, IL-13, but not IL-5, release was entirely
dependent on serine proteases within Alternaria.Alternaria-derived serine protease activity
exacerbates allergic airway disease
Because Alternaria is associated with fatal asthma exacerba-
tions, we developed a murine model of allergen-mediatedexacerbation (Fig 4, A) to determine whether the capacity of
Alternaria serine proteases to drive a robust inflammatory
response contributed to a sudden enhancement in disease severity.
Mice were treated with HDM for 3 weeks and then 24 hours
before being culled were exposed to a single dose of Alternaria.
HDM induces bronchiolar epithelial cells to change to a
mucus-secreting phenotype (Fig 4, B-D).33 Accordingly, all
HDM-treated groups showed an increase in MUC5AC and
MUC5B message in lung tissue relative to controls (Fig 4, B
and E3, A [in this article’s Online Repository at www.
jacionline.org]). However, mice previously treated with HDM
for 3 weeks responded to Alternaria by releasing mucus into
the airway lumen, which was dependent on the serine protease
activity of the allergen (Fig 4, C and D). This was confirmed
via a Western blot, which depicted increased MUC5AC in
the BALF of HDM-Alternaria mice (Fig E3, B). The
Alternaria-induced mucus secretion was associated with an
increase in baseline elastance and a decrease in baseline dynamic
FIG 3. Cell recruitment to the lungs occurs within 24 hours. Mice were treated with either HDM or Alternaria
(Alt). Total cells (A), neutrophils (B), eosinophils (C), tissue macrophages (D), IL-13 (E), and IL-5 (F) levels in
the BALF. Data are presented as mean 6 SEM (8-10 mice per treatment group). *P < .05 compared with
PBS-treated mice. P < .05 compared with Alternaria-treated mice.
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and F), which indicated that mucus plugging of the airways in
response to this allergen increases the rigidity of the lungs and
decreases their ability to expand and recoil. Similarly,
methacholine-induced elastance was increased in the Alterna-
ria-treated allergic mice (Fig 4, G). Airway resistance
(a function of smooth-muscle contraction of the conducting
airways) although increased was not significantly exacerbated
by instillation of Alternaria (Fig 4, H).
Exposure of mice with HDM allergy to Alternaria resulted in a
dramatic eosinophil influx into the airways (Fig 5, A). This
eosinophilia was reduced through treatment with AEBSF, which
implicates allergen-derived serine proteases in the exacerbated
inflammation. Similarly, tissue macrophages (Fig 5, B) and
neutrophils (Fig 5, C) were significantly elevated in the airways
of Alternaria-exposed HDM-allergic mice. The increase in
macrophages was partially dependent on Alternaria serine
proteases (Fig 5, B), whereas the number of neutrophils was
independent (Fig 5, C). ILC2 cells, which were increased after 3
weeks of HDM treatment, trebled in response to Alternariachallenge, an effect dependent upon serine protease activity (Fig
5, D). The influx of TH cells was not reliant on proteases (Fig 5,
E-G). However, IL-13 release, which was augmented in allergic
mice, was completely dependent on protease activity (Fig 5, H).
DISCUSSION
Fungal allergens are a common cause of allergic asthma, with
Alternaria alternata implicated not only in the development
and persistence of asthma but specifically in rapid onset life-
threatening exacerbations. We show that an Alternaria-specific
serine protease activity elicits the rapid release of IL-33, which
subsequently directs a robust early allergic inflammation
and furthermore can significantly exacerbate disease in mice pre-
viously sensitized to a disparate allergen. This Alternaria-specific
capacity to initiate the rapid and robust IL-33–dependent
pulmonary allergic inflammation may define why patients with
severe asthma exacerbations have frequently been exposed to
Alternaria.
Alternaria-induced elevations in extracellular ATP and
sustained augmentation of intracellular Ca21 concentrations
FIG 4. Exacerbation of HDM-induced allergic airway disease byAlternaria. Mice were treated with HDM and
received a final challenge with Alternaria (Alt). A, Schematic of exacerbation protocol. B, qPCR of MUC5AC
transcript. C, Mucous score and periodic acid–Schiff staining of paraffin section, showing mucous (pink
staining) (D). E, Baseline elastance and baseline compliance (F). G, Elastance at 100 mg/mL methacholine
(MCh). H, Airway resistance to increasing doses of methacholine. Data are presented as mean 6 SEM
(4-6 mice per treatment group). Representative photomicrographs are shown. Original magnification 340.
Scale bar 5 50 mm. *P < .05 compared with PBS-treated mice. P < .05 compared with HDM-treated mice.
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FIG 5. Alternaria results in inflammatory cell influx in allergic mice. Mice were treated with HDM and
received a final challenge with Alternaria (Alt). Eosinophils (A), tissue macrophages (B), neutrophils
(C), Lin2 IL-131 ILC2 cells (D), CD41 IFN-g1 TH1 (E), CD4
1 IL-171 TH17 (F), and CD4
1 IL-131 TH2 cells in the
BALF (G). H, IL-13 levels in the BALF determined by ELISA. *P < .05 compared with PBS-treated mice.
P < .05 compared with HDM or HDM ALT-treated mice. Data are presented as mean 6 SEM (4-6 mice
per treatment group).
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Accordingly, we observed Alternaria-induced release of
full-length IL-33 into the BALF of mice within 1 hour, which
was dependent on ATP signalling. Importantly, we further defined
the mechanism whereby Alternaria elicits IL-33 release, which
demonstrates it to be dependent upon serine protease activity of
the allergen and induced via activation of PAR-2. We propose a
model whereby an Alternaria-specific protease activates PAR-2,
which causes elevated extracellular ATP that, in turn, drives the
release of preformed IL-33. This dependence of Alternaria
intrinsic serine protease activity in driving this IL-33–mediated
inflammation could underlie the potential of fungal proteases to
act as TH2 adjuvants.
27,28 A recent study demonstrated that
fungal-derived proteases cleave fibrinogen, which subsequently
elicits allergic inflammation via TLR4 signalling,29 a mechanism
that could also contribute to our observed Alternaria-specific
phenotype. Furthermore, it is conceivable that crosstalk between
TLR4-TRIF and PAR-2-TRIF signalling pathways drives allergic
inflammation in response to Alternaria, as has been demonstrated
in lipopolysaccharide models.34,35
As with IL-33, early release of IL-1b was dependent on
Alternaria serine protease activity and ATP signaling but did not
lie downstream of IL-33 signaling. ATP is a known stimulus
that drives the release of IL-1b,36,37 and it would seem that an
ATP-dependent pathway regulates release of IL-1 family
proteins, IL-33 and IL-1b. Intriguingly, release of MCPT-1 and
MMP-9 in response to Alternaria was not only dependent on
intrinsic serine protease activity but was also secondary to IL-
33 release. Both MCPT-138 and MMP-939-42 are implicated in
the development of allergic airway disease, although this is the
first study to demonstrate that their release is IL-33 responsive.
We subsequently demonstrated that Alternaria elicited a rapid
pulmonary inflammation by 24 hours after challenge, which was
primarily neutrophilic, and was serine protease and ST2 depen-
dent. A capacity of IL-33 to drive neutrophilic inflammation43-47
has been reported but not previously in the lung. Alternaria
challenge also elicited an eosinophilic inflammation by 24 hours,
not observed with HDM. The eosinophilia was dependent on
serine protease activity of Alternaria and contingent on IL-33.
The potential of IL-33 to promote IL-548,49 and CCL248 release
could contribute to this observed eosinophilia. This unique
capacity of the Alternaria serine protease–IL-33 axis to drive
an early pulmonary inflammation is supportive of clinical data
that describe the potential of Alternaria spore exposure to
compromise respiratory status of individuals within 24 hours
and the more rapid onset of severe disease.50
Alternaria is associated with sudden, severe exacerbations of
asthma.24,25 and, therefore, we developed an exacerbation
model of allergic airway disease. The level of eosinophilia is
seemingly a biomarker for asthma exacerbations.51-54 Exposure
of HDM- sensitized mice to Alternaria resulted in a dramatic
augmentation of eosinophilic inflammation that was seemingly
fungal intrinsic serine protease activity dependent and, there-
fore, potentially contingent on IL-33. Alternaria exacerbation
also resulted in a pronounced increase in numbers of infiltrating
macrophages and ILC2 cells that were found to be reliant on
serine protease activity. In ovalbumin-induced models of
allergic airways disease, ST2 has been shown to be dispensable
for TH2 inflammation.
55 It is feasible that the role for ST2 is
pronounced in our studies because of the protease pathway
unique to Alternaria that elicits the release of IL-33.Furthermore, allergen sensitization is mediated by alum in oval-
bumin models, which skews the immune response to a TH2
phenotype potentially bypassing a dependence on the innate
pro-TH2 cytokine IL-33 signaling via its receptor ST2, which
drives disease development after inhaled allergen.
Allergic mice responded to Alternaria instillation by releasing
mucus into the airway lumen, which again was dependent on the
serine protease activity of the allergen. This elevated mucus
release may be driven by the observed changes in the IL-33
responsive cytokine, IL-13. The mucus plugging of the airways
and significantly elevated cellular infiltrate in Alternaria-
exacerbated mice likely accounted for the observed reduction
in baseline elastance and increase in compliance. Thus, our
model of asthma exacerbation elicited by Alternaria challenge re-
capitulates many of the cellular, structural, and physiological
manifestations observed clinically, and intrinsic to these dramatic
alterations is the aeroallergen serine protease activity and
presumably its capacity to drive IL-33 release.
This study significantly augments our understanding of the
pathogenicity of fungal aeroallergens. Specifically, we showed
(1) Alternaria-driven release of IL-33 was attributable to a
serine protease activity specific to this aeroallergen, (2)
MMP-9 and MCPT-1 are novel downstream targets of IL-33,
(3) the Alternaria intrinsic serine protease–IL-33 axis elicits
a robust, rapid inflammation that may underlie the capacity
of fungal proteases to act as TH2 adjuvants, and (4) the
propensity of Alternaria serine protease activity to drive
IL-33 release and ensuing inflammation rationalizes the clinical
relevance of this aeroallergen at inducing severe rapid,
onset asthma exacerbations. Given the increasing prevalence
of fungal aeroallergens, it may be prudent to target this
protease-IL-33 axis therapeutically in these instances of severe
and exacerbated asthma.
We thank Lorraine Lawrence for histologic sectioning and staining.
Key messages
d An Alternaria-specific serine protease activity, which is
lacking from other common aeroallergens, drives the
robust early release of IL-33.
d This serine protease–IL-33 axis promotes pronounced
pulmonary inflammation and innate mediator release.
d The rapid influx of innate lymphoid cells and eosinophils
and mucus release into the airways in the allergic lung
underlies the Alternaria-specific rapid exacerbation of
allergic airway disease and decrease in lung function
associated with severe asthma and fatal asthma attacks.REFERENCES
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HYPERRESPONSIVENESS
Measurements of dynamic resistance and compliance were
performed by using the Flexivent system (Scireq, Montreal,
Quebec, Canada). After induction of anesthesia with an intraper-
itoneal injection of pentobarbitone (50 mg/kg) (Sigma-Aldrich)
and intramuscular injection of ketamine (200 mg/kg) (Fortdodge
Animal Health Ltd, Southampton, United Kingdom), mice were
tracheostomized and connected to the Flexivent ventilator via a
blunt-ended 19-gauge needle. Mice were ventilated by using the
following settings: tidal volume of 7 mL/kg body weight, 150
breaths/minute; positive end-expiratory pressure approximately 2
cm H2O. Standardization of the lung volume history was done by
performing 2 deep inflations. Subsequently, measurements of
airway function were made. Measurements of resistance,
elastance, and compliance were determined from a user-defined
protocol by using the snapshot-150 perturbation, which is a
single-frequency sinusoidal waveform. Resultant data were fitted
by using multiple linear regression to the single compartment
model to determine the above parameters. The resultant data
was fitted to the Constant-Phase model to determine the above
parameters. Changes in lung-airway function parameters were
measured in response to increasing concentrations of nebulized
methacholine from 3-100 mg/mL, delivered into the inspiratory
line of the flexivent ventilator. Airway resistance was expressed
as cmH2O/mL/s, elastance was expressed as cmH2O/mL, and
compliance was expressed as mL/cmH2O.
Collection and preparation of samples
BALFwas collected by lavage of the lungs 3 times with 0.4 mL
of PBS via a tracheal cannula. BALF was centrifuged (700g,
5 minutes, 48C), and cells were resuspended in 0.5 mL complete
media (RPMI 1 10% FCS, 2 mM L-glutamine, 100 U/mL
penicillin/streptomycin). BALF cell supernatants were removed
and analyzed for mediators by ELISA. To disaggregate the cells
from the lung tissue, 1 lobe (approximately 100 mg) of lung
was incubated at 378C for 1 hour in digest reagent (0.15 mg/mL
collagenase type D, 25 mg/mL DNase Type I) in complete
RPMI media. The recovered cells were filtered through a
70-mm nylon sieve, washed twice, resuspended in complete
media, and counted in a hemocytometer before FACS analysis.
Assessment of airway remodeling
Goblet cells were visualized on periodic acid–Schiff stained lung
sections and scored with results expressed as a mucus score in
arbitrary units.E1,E2 Periodic acid–Schiff stained goblet cells in
airway epitheliumweremeasured double-blind by using a numerical
scoring system (0, <5%goblet cells; 1, 5% to 25%; 2, 25% to 50%; 3,
50%to75%;4,>75%).The sumof airway scores fromeach lungwas
divided by the number of airways examined, 20 to 50 airways per
mouse, and expressed as mucus cell score in arbitrary units.
FACS
Single-cell suspensions were stained with the LIVE/DEAD
Fixable Near-IR-Dead Cell staining kit (Molecular Probes,
Invitrogen) for 10 minutes in PBS. Cells then were washed in
PBS and stained for surface markers for 30 minutes at 48C in PBS
that contained 0.1% (wt/vol) sodium azide and 1% (wt/vol) BSA
and were fixed with 2% (vol/vol) paraformaldehyde. Cell types
were characterized according to their forward- and side-scatterprofiles and by their phenotype as follows: neutrophils, Ly6
GhiCD11bhiCD11c2F4/80lo; eosinophils, SiglecFhiLy6GloCD
11bhi; alveolar macrophages, CD11bneg-loCD11c1F4/80hi; tissue
macrophages, CD11bhiCD11c2F4/80hi; T lymphocytes,
CD31CD41 or CD31CD81; ILC2s, Lin2CD451ICOS1.
For the detection of intracellular cytokines, 1 3 106 cells
per mL were incubated for 3 hours at 378C with phorbol
12-myristate 13-acetate (50 ng/mL), ionomycin (500 ng/mL;
Calbiochem, Nottingham, United Kingdom) and brefeldin
A (10 mg/mL). Cells then were stained with anti-CD4 and
anti-CD8 (for T lymphocytes) or anti-Lin, anti-CD45, and
anti-ICOS (for ILC2s) and fixed as described above. After being
made permeable for 10 minutes with a buffer of 1% (wt/vol)
saponin, 1% (wt/vol) BSA, and 0.05% (wt/vol) azide in PBS
(saponin buffer), cells were stained with anti-IFN-g, anti-IL-17,
and anti-IL-13 diluted 1:50 in saponin buffer. Then, 30 minutes
later, cells were washed once in saponin buffer and once in PBS
that contained 0.1% (wt/vol) sodium azide and 1% (wt/vol)
BSA, and data were acquired on a Fortessa, which collected 5
3 104 lymphocyte events that were analyzed with FACSDiva
software (BD Bioscience).
MMP-9 zymogram
BALF was mixed with an equal volume of Novex Tris Glycine
SDS sample buffer (Invitrogen) and electrophoresed on Novex
10% zymogram (gelatine) gels (Invitrogen) at 125 V for 90
minutes. After electrophoresis, gels were incubated in Zymogram
Renaturing Buffer (Invitrogen) for 30 minutes at room
temperature. To visualize the gelatinolytic activity, the gel was
incubated in Zymogram Developing Buffer (Invitrogen)
overnight at 378C before staining with SimplyBlue Safestain
(Invitrogen).
RNA extraction and real-time PCR
Total RNAwas extracted from 50 to 100 mg of lung tissue by
using the Qiagen RNeasy Mini Kit (Qiagen, Manchester, United
Kingdom); cDNA was synthesized from 1 mg of total RNA
prepared with the Moloney Murine Leukemia Virus (M-MLV)
reverse transcriptase mix (Promega, Madison, Wis) and analyzed
by means of PCR on a CFX96 real-time PCR detection system
(Bio-Rad Laboratories, Hemel Hempstead, United Kingdom).
Reactions were run in triplicate with TaqMan probes (Applied
Biosystems, Invitrogen) and TaqMan Fast Advanced MasterMix
(Applied Biosystems, Invitrogen). The expression of the
MUC5AC (Applied Biosystems probe Mm0127626_g1) and
MUC5B gene (Applied Biosystems probe Mm00466391_m1)
was normalized against that of hypoxantine phosphoribosyltrans-
ferase (probe Mm01545399_m1; Applied Biosystems).
Western blot
All the samples were electrophoresed through reducing
SDS-polyacrylamidegels andwere electroblottedontonitrocellulose
membranes. Membranes were blocked in TRIS-buffered saline
solution that contained 5% milk for 1 hour at 228C and were
incubated overnight at 48C with primary antibody to Muc5AC
(2-11M1;1mg/mL;Abcam,Cambridge,UnitedKingdom) diluted in
TRIS-buffered saline solution that contained 5%milk.Oncewashed,
the membranes were incubated with goat anti-mouse IgG-horse-
radish peroxidase (1/5000; Invitrogen), and reactivity was detected
by using enhanced chemiluminescence (ECL) chemiluminescent
kits (Pierce, Rockford, Ill) according to manufacturer’s directions.
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FIG E1. Innate mediator release in the BALF after allergen challenge. Mice were treated with extracts of
either HDM, Alternaria (ALT), cat dander (CAT), ragweed (RAG), or the proteases papain (PAP) or trypsin
(TRYP). B denotes boiled extract. A, Total cells. B, IL-33 levels in the lung 1 hour after PBS or ALT exposure.
C, Lactate dehydrogenase, uric acid (D), albumin levels (E) in the BALF. Data are presented as mean 6 SEM
(8-10 mice per treatment group). *P < .05 compared with PBS-treated mice.
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FIG E2. Protease activity of allergen extracts. A, Total protease activity of HDM and Alternaria (ALT).
B, Serine/cysteine protease activity determined bymetabolism of the serine and cysteine protease substrate
N-Benzoyl-Phe-Val-Arg-p-nitroanilide (NBP-VANA). Data are presented as mean 6 SEM (n 5 4). C, IL-33
levels in the BALF 1 hour after exposure to allergen. Data are presented as mean 6 SEM (4-6 mice per treat-
ment group).
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FIG E3. Alternaria induces mucus release in the exacerbation model. A, Fold increase in transcript for
MUC5B determined by qPCR. B, Western blot for mucin 5AC in the BALF of mice exposed to HDM and
subsequently treated with either Alternaria in the presence or absence of AEBSF or PBS. Data are 4-6
mice per treatment group. *P < .05 compared with PBS-treated mice.
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TABLE E1. Allergen extracts (1 mg/mL HDM, 100 mg/mL all
other allergens) were screened by using 8 protease inhibitors
(ProteSEEKER assay) to determine protease classes present in
the extracts*
Inhibitor HDM ALT CAT RAG
Bestatin
Aminopeptidases, exopeptidases 0 6.5 2.8 0
E-64
Cysteine proteases 24.4 0 7.8 2.1
EDTA
Metalloproteases 0 1.6 2.3 0
Leupeptin
Serine and cysteine proteases 17.9 8.9 22.9 24.2
Pepstatin
Aspartic proteases 0 5.7 21.1 0
AEBSF
Serine proteases 11.5 26.0 33.5 17.9
Phosphoramidon
Thermolysin, collagenase, metalloendoproteinases 6.4 24.0 11.0 12.6
Phenylmethanesulfonylfluoride (PMSF)
Serine and cysteine proteases 0 35.0 28.4 87.4
*Results represent % inhibition of protease activity.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2014
592.e6 SNELGROVE ET AL
